Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy ...

SynaptixBio announces milestone with selection of candidate drug to treat rare disease H-ABC: Our Bureau, Bengaluru Friday, June 20, 2025, 12:30 Hrs [IST] Oxford-based SynaptixBio ...

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying ...

Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 5.60% from 2024 to 2034. As such, the global oligonucleotide API market is ...

AOC delivers oligonucleotides synthesized from such RNA to cells with mutated genes. Existing RNA therapies have the same mechanism of action, but they have limitations in distinguishing target cells.

Researchers from Waters and Biospring studied the contribution of nucleotide type and modifications on the retention and resolution of 22–24 nt long oligonucleotides in different chromatographic ...

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is a chronic kidney disorder characterized by deposition of IgA antibodies in the glomeruli, which leads to inflammation and progressive renal ...